Adagene doses first subject in Phase II MSS colorectal cancer trial
I'm PortAI, I can summarize articles.
Adagene has initiated its Phase II trial for ADG126, an anti-CTLA-4 therapy, in combination with Keytruda for treating microsatellite stable colorectal cancer (MSS CRC) without liver metastases. The trial aims to evaluate overall response rate as the primary endpoint, with secondary endpoints including overall survival, duration of response, and progression-free survival. The study will randomize participants to receive either 10mg/kg or 20mg/kg doses. The trial is expected to conclude in early 2027, following FDA alignment on endpoints and designs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: WorldPharmaceuticals The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments